Prostate cancer: score one for validated targets.
نویسنده
چکیده
This CCR Focuswent to press shortly after the Food and Drug Administration (FDA) approval, on April 28, 2011, of abiraterone in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. Abiraterone was synthesized in the early 1990s by Mike Jarman’s group at the Institute of Cancer Research, Sutton, Surrey, England. After some delay, clinical development was initiated under the leadership of Johann de Bono, who conducted phase I, II, and III trials, with activity observed at each stage. Several aspects of this are notable. One, this is the third major regulatory approval in the space of 1 year for a disease that once had few treatment options after testosterone-lowering therapy. Second, approvals of all 3 were based on an overall survival advantage, a feat that many have argued has become impossible in oncology. Third, the approvals were for drugs against old targets, microtubules and the androgen receptor, and in the case of sipuleucel-T, a new approach in an established treatment paradigm (i.e., immunotherapy). The irony of this should not be lost in the age of targeted therapies, with the steady expansion of exotic new targets as well as the exhaustive list of kinase inhibitors/ antiangiogenic agents in development. Taken together, these studies represent the type of achievement that shows oncology at its best—incremental steps that instruct us in the biology of cancer while providing true clinical benefit. The clinical trial results clearly meet the ‘‘substantial evidence’’ criteria of adequate and well-controlled investigations anticipated when the U.S. Congress adopted the 1962 Drug Amendments requiring ‘‘manufacturers of drug products to establish a drug’s effectiveness by substantial evidence’’ (1, 2). It is fitting that de Bono and Gerhardt Attard, who also participated in abiraterone development, serve as Guest Editors of this issue of CCR Focus. They have recruited a series of experts to discuss the new developments: Massard and Fizazi to discuss continued androgen receptor signaling; Madan, Pal, Sartor, and Dahut to discuss cabazitaxel and other small molecules in development; and Gulley and Drake to discuss sipuleucel-T and other immunotherapies. These articles are complemented by a discussion by Danila, Fleisher, and Scher of circulating tumor cells as biomarkers, also the subject of an FDA device approval in 2009. As with every issue of CCR Focus, this issue is meant to be accessible to those interested but nonexpert in this topic, to stimulate the thinking of those working in the field, and to highlight concepts for future research.
منابع مشابه
Secondary cancers during the radiotherapy of prostate cancer: a review article
Prostate cancer is the most common and second leading cause of death among men in the world. Nowadays, radiotherapy has been known as one of the most affecting methods for prostate cancer treatment. Nevertheless, radiotherapy is accompanied by the concern of developing secondary cancers by the scattered radiation to the neighbor organs at risk. Several studies have shown that secondary cancers...
متن کاملHealth Literacy and Men\'s Attitudes and Practices toward Prostate Cancer Screening
Background: Health literacy as a vital indicator of health care costs plays an important role in facilitating effective health communication strategies. Screening is one of these strategies, so that intervention and management can be provided ahead of schedule. The aim of this study was to determine the relationship between health literacy and men's practices and their attitude toward prosta...
متن کاملEvaluation of Anti-cancer activity of Boswellic acid and Montelukast sodium against human prostate cancer cell line PC-3
Prostate cancer is a devastating disease for which current therapies are inadequate. Various lines of evidences have suggested the 5-lipoxygenase (5-LOX) pathway and the leukotriene receptor pathway are potential targets for prevention or treatment of Prostate cancer. Thus, search for new anti-cancer drugs targeting 5-LOX and leukotriene is very essential and important. The objective of the pre...
متن کاملGrading of prostatic adenocarcinoma: current state and prognostic implications
BACKGROUND Despite significant changes in the clinical and histologic diagnosis of prostate cancer, the Gleason grading system remains one of the most powerful prognostic predictors in prostate cancer. The correct diagnosis and grading of prostate cancer is crucial for a patient's prognosis and therapeutic options. However, this system has undergone significant revisions and continues to have d...
متن کاملEffectiveness and complications of 153Sm-EDTMP in palliative treatment of diffuse skeletal metastases
Introduction: The aim of the present study was to evaluate the efficacy and safety profile of bone palliative therapy following administration of 153Sm-EDTMP in patients with intractable metastatic bone pain. Methods: Sixteen patients (9 male, 7 female) aged 29-80 years (57.3±16.7 years) with severe metastasis-related bone pain resistant to analgesic medications were enrolled in the...
متن کاملmiR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation.
MicroRNAs (miRNA) have been globally profiled in cancers but there tends to be poor agreement between studies including in the same cancers. In addition, few putative miRNA targets have been validated. To overcome the lack of reproducibility, we profiled miRNAs by next generation sequencing and locked nucleic acid miRNA microarrays and verified concordant changes by quantitative RT-PCR. Notably...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical cancer research : an official journal of the American Association for Cancer Research
دوره 17 12 شماره
صفحات -
تاریخ انتشار 2011